ACE2 IHC Antibody / Angiotensin Converting Enzyme 2 Tissue Expression Antibody

Angiotensin I Converting Enzyme 2 Antibody Overview

Angiotensin converting enzyme 2 (ACE2) is a membrane-associated protein with well-defined tissue distribution that makes it highly suitable for immunohistochemistry-based detection. ACE2 IHC antibody reagents are widely used to visualize protein localization in formalin-fixed, paraffin-embedded samples, enabling detailed analysis of epithelial and endothelial compartments across multiple organ systems. This tissue-focused approach provides critical spatial context for understanding ACE2 expression in both normal physiology and disease.

ACE2 IHC antibody, also known as Angiotensin converting enzyme 2 immunohistochemistry antibody or ACE-2 antibody, is commonly used to evaluate expression in lung, kidney, intestinal, and vascular tissues. In lung, staining is typically observed in alveolar epithelial cells, while kidney sections show prominent expression in proximal tubular epithelium. Intestinal enterocytes demonstrate strong membranous staining, reflecting ACE2’s role in epithelial function and barrier regulation. These consistent patterns support the use of ACE2 IHC antibody for tissue-based expression profiling.

Tissue microarray (TMA) analysis significantly enhances the utility of ACE2 IHC antibody by enabling high-throughput evaluation across a wide range of normal and cancer tissues. TMA-based immunohistochemistry allows direct comparison of staining intensity and localization under standardized conditions, commonly revealing membranous and apical staining in epithelial cell populations. These findings align with established expression datasets and support reproducible assessment of ACE2 distribution across tissue types.

ACE2 is also a key receptor for SARS-CoV-2, making tissue-level detection particularly relevant for studies of viral entry and tissue susceptibility. Immunohistochemical localization using ACE2 IHC antibody allows identification of specific cell types expressing the receptor, providing insight into infection patterns and disease progression. This has made ACE2 a central focus in respiratory and infectious disease research.

In addition to infectious disease applications, ACE2 IHC antibody is used to investigate cardiovascular, renal, and inflammatory conditions where tissue-specific expression changes are important. Immunohistochemistry enables precise localization within defined cell populations, supporting analysis of disease-associated remodeling and signaling alterations.

👉 A well-characterized ACE2 antibody for IHC, clone MSVA-919R, has been validated using human tissue microarrays and demonstrates consistent epithelial staining across multiple tissues.

ACE2 Tissue Expression in Normal Organs

ACE2 expression is most prominent in epithelial-rich tissues, including lung alveoli, renal tubules, and intestinal mucosa. Immunohistochemical staining highlights membranous localization consistent with its function as a surface enzyme and receptor.

ACE2 Expression in Cancer Tissues

In tumor samples, ACE2 expression varies by tissue of origin, with detectable staining in subsets of renal, gastrointestinal, and hepatocellular carcinomas. Tissue microarray analysis enables comparative evaluation across multiple tumor types under uniform conditions.

ACE2 TMA-Validated IHC Analysis

Use of ACE2 IHC antibody in tissue microarray formats allows rapid screening of expression patterns across diverse tissues. This approach supports identification of tissue-specific expression trends and validation of staining reproducibility.

A selection of ACE2 antibody products is shown below to support tissue-based research applications.

This ACE2 antibody page is part of a broader antibody panel offered by NSJ Bioreagents.